Participants
The main inclusion criteria of the participants were as follows: 1) adult subjects aged 18–65 years old who were treatment-naive or had terminated their treatment at least six months for nucleoside analog use or at least one year for interferon use prior to screening; 2) showing serum HBV DNA ≥ 2 × 10